The Christie Hospital breast conservation trial: an update at 8 years from inception.

2.50
Hdl Handle:
http://hdl.handle.net/10541/99802
Title:
The Christie Hospital breast conservation trial: an update at 8 years from inception.
Authors:
Ribeiro, G; Magee, Brian; Swindell, Ric; Harris, Martin; Banerjee, Saumitra S
Abstract:
In 1990, we published the results of a clinical trial involving 708 patients with breast carcinoma of 4 cm or less in diameter, who, following lumpectomy, were randomized to have radiotherapy to the tumour bed only (limited field, LF group) or to the whole breast and regional nodes (wide field, WF group). No adjuvant systemic therapy was prescribed. At the time the median follow-up was 37 months. We present the updated results after an extended median follow-up of 65 months. The overall survival is 72.7% and 71.2% for the LF and WF groups respectively. The actuarial breast recurrence rate (first event) is 15% (LF) versus 11% (WF) for infiltrating ductal carcinoma, whereas, for infiltrating lobular carcinoma, the recurrence rate was 34% (LF) versus 8% (WF). A high actual recurrence rate of 21% (LF) and 14% (WF) was also found for extensive ductal carcinoma in situ. It was extremely rare for medullary, mucoid or tubular carcinomas to recur. Salvage surgery was possible in 86% (LF) and 90% (WF) respectively. The recurrence rate in the breast following lumpectomy and wide field irradiation is comparable with others reported in the literature. This trial also shows the lumpectomy with limited field irradiation is feasible, albeit with a higher breast recurrence rate; the latter could be reduced by improved selection and refinement of the technique.
Affiliation:
Department of Clinical Oncology, Christie Hospital NHS Trust, Manchester, UK.
Citation:
The Christie Hospital breast conservation trial: an update at 8 years from inception. 1993, 5 (5):278-83 Clin Oncol
Journal:
Clinical Oncology
Issue Date:
1993
URI:
http://hdl.handle.net/10541/99802
DOI:
10.1016/S0936-6555(05)80900-8
PubMed ID:
8305334
Type:
Article
Language:
en
ISSN:
0936-6555
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorRibeiro, Gen
dc.contributor.authorMagee, Brianen
dc.contributor.authorSwindell, Ricen
dc.contributor.authorHarris, Martinen
dc.contributor.authorBanerjee, Saumitra Sen
dc.date.accessioned2010-05-25T11:44:57Z-
dc.date.available2010-05-25T11:44:57Z-
dc.date.issued1993-
dc.identifier.citationThe Christie Hospital breast conservation trial: an update at 8 years from inception. 1993, 5 (5):278-83 Clin Oncolen
dc.identifier.issn0936-6555-
dc.identifier.pmid8305334-
dc.identifier.doi10.1016/S0936-6555(05)80900-8-
dc.identifier.urihttp://hdl.handle.net/10541/99802-
dc.description.abstractIn 1990, we published the results of a clinical trial involving 708 patients with breast carcinoma of 4 cm or less in diameter, who, following lumpectomy, were randomized to have radiotherapy to the tumour bed only (limited field, LF group) or to the whole breast and regional nodes (wide field, WF group). No adjuvant systemic therapy was prescribed. At the time the median follow-up was 37 months. We present the updated results after an extended median follow-up of 65 months. The overall survival is 72.7% and 71.2% for the LF and WF groups respectively. The actuarial breast recurrence rate (first event) is 15% (LF) versus 11% (WF) for infiltrating ductal carcinoma, whereas, for infiltrating lobular carcinoma, the recurrence rate was 34% (LF) versus 8% (WF). A high actual recurrence rate of 21% (LF) and 14% (WF) was also found for extensive ductal carcinoma in situ. It was extremely rare for medullary, mucoid or tubular carcinomas to recur. Salvage surgery was possible in 86% (LF) and 90% (WF) respectively. The recurrence rate in the breast following lumpectomy and wide field irradiation is comparable with others reported in the literature. This trial also shows the lumpectomy with limited field irradiation is feasible, albeit with a higher breast recurrence rate; the latter could be reduced by improved selection and refinement of the technique.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectCancer Recurrenceen
dc.subject.meshAged-
dc.subject.meshBreast Neoplasms-
dc.subject.meshCarcinoma in Situ-
dc.subject.meshCarcinoma, Ductal, Breast-
dc.subject.meshCarcinoma, Lobular-
dc.subject.meshCombined Modality Therapy-
dc.subject.meshFemale-
dc.subject.meshFollow-Up Studies-
dc.subject.meshGreat Britain-
dc.subject.meshHumans-
dc.subject.meshMastectomy, Segmental-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Recurrence, Local-
dc.subject.meshRadiotherapy-
dc.subject.meshSurvival Rate-
dc.titleThe Christie Hospital breast conservation trial: an update at 8 years from inception.en
dc.typeArticleen
dc.contributor.departmentDepartment of Clinical Oncology, Christie Hospital NHS Trust, Manchester, UK.en
dc.identifier.journalClinical Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.